Comparing the antifibrotic effect on the liver of Telmisartan and Pentoxifylline, in a Wistar rat experimental model

Vol. 58 No. 4, 2017


Floriana Elvira Ionica, Laurentiu Mogoanta, Simona Negres, Ludovic Everard Bejenaru, Oana Mariana Cristea, Oana Badea, Cornelia Bejenaru

Chronic liver diseases are characterized by higher or lower changes of the liver lobe architecture (parenchymatous and vacuolar), the accumulation of inflammatory and collagen infiltrates, mainly in the Kiernan spaces and a progressive evolution to liver cirrhosis. Despite the progresses made in knowing the mechanisms of liver fibrosis and the development of some antiviral drugs with a high potential, that can induce fibrosis regression, there still continues to exist the need for a specific antifibrotic treatment. In our study, we used four groups of Wistar rats: a reference group and three groups that received 40% carbon tetrachloride (CCl4), intraperitoneally, twice a week, for four weeks; after one week since starting the administration of CCl4, one of the three groups received, through oral gavage, Telmisartan (TS) 8 mg/kg, and another received Pentoxifylline (PTX) 20 mg/kg, dissolved in saline solution, for four weeks. The antifibrotic action of the two drugs was analyzed by evaluating the histopathological and immunohistochemical changes of hepatocytes, hepatic stellate cells (Ito cells) and macrophages (Kupffer cells). The study highlighted that in the group treated with TS, the process of fibrillogenesis was significantly reduced, in comparison to the group treated with PTX and with the reference group.

Corresponding author: Ludovic Everard Bejenaru, Associate Professor, Biol, Pharm, PhD; e-mail:

Download PDF